Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 85 years old
- People who have been diagnosed with a specific type of pulmonary hypertension (high blood pressure in the lungs) called Combined pre-/post-capillary PH, confirmed by specific pressure measurements taken during a heart catheter procedure (confirm with trial site)
- People whose heart failure symptoms fall within a certain range of severity, classified as NYHA Class I, II, or III (confirm with trial site)
- People who have had a qualifying heart catheter procedure (right heart catheterisation) within the past 2 years, and a heart ultrasound (echocardiogram) within the past year showing the heart is pumping at a certain level of strength (confirm with trial site)
- People whose medications for pulmonary hypertension and/or heart failure have been stable, with no more than one diuretic (fluid tablet) dose change in the three months before enrolling
- People who are able to walk and complete a walking test
Who may not be able to join:
- People whose pulmonary hypertension is caused by a congenital (present from birth) heart condition, a connective tissue disease, or an inherited form of the condition
- People who are unable to move around freely due to being wheelchair-bound, bed-bound, reliant on a cane or walker, or limited by chest pain, severe joint problems, or other conditions that restrict activity
- People who are pregnant
- People with pulmonary hypertension linked to drug or toxin use who are still actively using those substances
- People who have previously been diagnosed with, or currently have, cirrhosis (scarring of the liver)
- People who currently have an active cancer diagnosis
- People with moderate to severe liver problems, as measured by specific medical scoring systems or elevated liver enzyme levels in blood tests (confirm with trial site)
- People whose kidneys are not functioning above a certain level, as measured by a specific blood test (confirm with trial site)
- People with significantly reduced lung function on breathing tests, combined with more than mild abnormalities seen on lung imaging (confirm with trial site)
- People who are currently enrolled in, or have completed, another clinical trial involving an investigational treatment within the past 30 days
- People who have been hospitalised for any reason within the 30 days before the trial start date
- People who have a history of a severe allergic reaction or hypersensitivity to NR (the treatment being studied)
- People who do not have a known mutation in a specific gene called NDUFB7 (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Evan L Brittain, MD, VUMC
Phone: 615-936-0156
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Biochemical: Change in NADH:Ubiquinone Oxidoreductase Subunit B7; Exploratory physiological measure: Change in 6-minute walk distance
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.